Apellis shares rallied after Goldman Sachs raised its price target to ₹2,170, citing Syfovre's strong Q2 sales and FDA approval for Empaveli in rare kidney diseases. Syfovre led with ₹12,600 crore in revenue, while Empaveli's new uses could unlock major upside. Retail sentiment turned 'extremely bullish' on Stocktwits amid surging message volume.